Neovascular age-related macular degeneration Trials in St. Petersburg, United States
Conditions / Neovascular age-related macular degeneration / St. Petersburg, United States
Neovascular age-related macular degeneration is a medical condition with active clinical research programs worldwide.
19 total trials for this combination
Showing top 10 of 19 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04423718 | Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye | COMPLETED | PHASE3 |
| NCT03577899 | Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) | TERMINATED | PHASE3 |
| NCT06223958 | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06495918 | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03677934 | A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration | COMPLETED | PHASE3 |
| NCT03345082 | A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD | COMPLETED | PHASE2 |
| NCT04757636 | OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) | TERMINATED | PHASE3 |
| NCT03683251 | Extension Study for the Port Delivery System With Ranibizumab (Portal) | RECRUITING | — |
| NCT04777201 | A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration | COMPLETED | PHASE3 |
| NCT04704921 | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | ACTIVE_NOT_RECRUITING | — |